Wall Street is closing out a strong quarter. Plus, Lilly's mixed obesity drug trial data

The S&P 500 was on track for a roughly 2.6% quarterly gain and the Nasdaq for a 3% gain, supported by a renewed AI trade despite rising oil prices and 10-year Treasury yields. Eli Lilly's EloraTZP mid-stage obesity trial delivered 23.3% weight loss versus 14.8% for high-dose tirzepatide alone, but more frequent adverse events pressured the stock and suggest a more niche role for the combination therapy. Micron's upcoming earnings are expected to show revenue up about 350% year over year to $51.07 billion and adjusted EPS up 943% to $31.61, underscoring continued AI-driven semiconductor expectations.

Analysis

The important cross-asset signal is the failure of softer inflation to pull down the long end: this is a term-premium/fiscal-supply regime, not simply a Fed-policy regime. That raises the discount-rate hurdle for long-duration software and pre-revenue AI beneficiaries even if near-term AI demand remains intact; MSFT, META and profitable cybersecurity leaders such as CRWD are better insulated than lower-quality application software because cash generation can offset part of the multiple pressure. Over the next 1-3 months, a further 25-40bp rise in the 10-year would likely rotate leadership from AI software toward semis, energy and financials rather than invalidate AI capex outright.

MU is the highest-event-risk AI read-through, but the cited consensus figures appear unusually large and should be independently verified before positioning. The market will price the stock on HBM supply, gross-margin trajectory, customer concentration and forward contract pricing—not backward-looking revenue growth; a strong print without an upward revision to HBM margins or FY capex visibility could produce a sell-the-news reaction. Conversely, a credible supply-tightness extension into 2027 would be constructive for MU and, secondarily, memory-equipment exposure, while pressuring AI system builders whose BOM costs are rising.

LLY's combination data increases the probability that the obesity franchise becomes segmented by efficacy and tolerability rather than governed by a single winner-take-most product. The adverse-event signal creates a meaningful Phase 3 execution risk and limits immediate value attribution to the combination; the more consequential 6-18 month issue is whether Lilly can preserve adherence and persistence as it moves patients through a broader portfolio. Consensus may be underweight the payer implication: better tolerability, rather than incremental peak weight loss, is what expands reimbursable patient-years and supports durable margins.

AAPL's incremental hardware categories are strategically more relevant to services attach and ecosystem retention than to near-term earnings. Foldables and a home hub can defend premium-device relevance, but each adds component complexity and competes against entrenched AMZN/GOOG home ecosystems; meaningful valuation upside requires evidence of gross-margin preservation and installed-base monetization, not unit estimates alone.

Key Decisions for Investors

• Maintain a 1-3 month quality-AI barbell: long MSFT and META versus a basket short of high-multiple, lower-free-cash-flow software. Use a 10-year Treasury yield sustained above 4.75% or a material AI-capex guidance cut as thesis-falsification signals; target 8-12% relative return with roughly 5% downside on the pair.
• Do not chase MU pre-results until reported HBM bit-growth, gross-margin guidance and customer concentration reconcile with independently sourced estimates. If each improves versus consensus, buy a 3-6 month post-earnings pullback; if revenue beats but gross-margin guidance disappoints, use a short MU/long SOXX relative trade for 1-2 months.
• Own LLY only as a core 6-18 month obesity-platform position, but avoid assigning material value to the combination program before Phase 3 tolerability data. Pair with a modest long NVO hedge to isolate category growth from molecule-specific safety risk; reduce if discontinuation rates fail to improve under optimized titration.
• Use AAPL as a watch item into launch and China sell-through data rather than a directional catalyst trade. Initiate only if premium-model demand translates into rising mix and gross-margin guidance; a China demand miss or evidence that foldable volumes cannibalize rather than expand the installed base would invalidate the upside case.
• Underweight HD and FDX for the next quarter while long yields remain elevated: housing turnover and freight volumes are more rate-sensitive than headline equity resilience implies. Reassess on a sustained 25bp+ decline in mortgage rates, improving housing turnover, or a clear inflection in industrial freight volumes.